Apremilast

證據等級: L5

預測適應症: 10 個

Apremilast: From Psoriatic Arthritis to Rheumatoid Arthritis

One-Sentence Summary

Apremilast (Otezla®) is an oral phosphodiesterase-4 (PDE4) inhibitor globally approved for psoriatic arthritis, plaque psoriasis, and Behçet's disease-related oral ulcers, but not currently registered in Singapore. The TxGNN model predicts Rheumatoid Arthritis as the highest-ranked indication with actual clinical supporting data (TxGNN score 98.09%), with 6 clinical trials and 19 publications on record — though the key Phase 2 trial was prematurely terminated, casting doubt on the clinical viability of this repurposing direction.

Note on TxGNN ranking: The model's top two scores belong to migraine disorder (98.66%) and migraine with brainstem aura (98.49%), but both carry L5 evidence (no clinical trials, no literature). Rheumatoid arthritis (rank 3, 98.09%) is the highest-ranked indication with meaningful supporting data and is therefore the focus of this report.

Quick Overview

Item	Content
Original Indication	Not registered in Singapore; globally approved for psoriatic arthritis and plaque psoriasis (Otezla®)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	98.09%
Evidence Level	L2
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Apremilast works by selectively inhibiting phosphodiesterase 4 (PDE4), the enzyme that degrades cyclic AMP (cAMP) inside immune cells. When PDE4 is blocked, intracellular cAMP rises, which suppresses the production of pro-inflammatory cytokines including TNF-α, IL-6, IL-17, and IL-23. This is precisely the mechanism behind its approved use in psoriatic arthritis and plaque psoriasis — both conditions characterised by Th1/Th17 immune axis overactivation.

Rheumatoid arthritis shares this same immunological core. The pathological drivers — synovial Th1/Th17 over-activation, excessive TNF-α and IL-6 secretion, progressive joint destruction — substantially overlap with psoriatic arthritis. Preclinical work has confirmed the translational rationale: Apremilast suppressed Th1 and Th17 cells while enhancing regulatory T-cell (Treg) differentiation in a collagen-induced arthritis mouse model (PMID 30072998), and directly inhibited spontaneous TNF-α production from human RA synovial tissue in vitro (PMID 20525198).

However, the clinical trajectory for RA tells a more cautious story. The largest Phase 2 RCT (NCT01285310, n=237 enrolled) was terminated early, and no programme has ever advanced to Phase 3. This pattern suggests that while the mechanism is biologically plausible, the magnitude of benefit in RA is likely insufficient to compete with the already well-established biological DMARDs (e.g., TNF inhibitors, IL-6 blockers) and JAK inhibitors now available as standard of care.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01250548	Phase 2	Completed	34	Randomised, placebo-controlled RA trial evaluating safety, time to response, and durability of effect — the best available direct positive evidence, though limited by small size (proof-of-concept level)
NCT01285310	Phase 2	Terminated	237	Largest RA Phase 2 RCT comparing two Apremilast doses vs placebo in MTX-inadequate responders; early termination is the most significant negative signal for this indication — termination rationale has not been publicly disclosed
NCT01204138	Phase 2	Withdrawn	0	Planned cross-over study of Apremilast add-on to TNF inhibitors in active RA; withdrawn before any enrolment — no data generated
NCT00521339	Phase 2	Completed	31	Open-label safety and PK study in recalcitrant plaque psoriasis; provides tolerability data relevant to the broader autoimmune disease context
NCT03036995	Phase 2	Completed	80	Apremilast combined with phototherapy in vitiligo; demonstrates broad immune-modulating reach in autoimmune skin disease but is not directly relevant to RA efficacy
NCT01504113	N/A	Unknown	100	Microbiome changes in psoriasis patients on targeted therapy; no RA efficacy data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25779750	2015	RCT	Arthritis & Rheumatology	Phase 2 multicenter double-blind RCT of Apremilast vs placebo in MTX-inadequate RA responders — primary publication of NCT01285310; reports efficacy and safety outcomes
30072998	2018	Animal Study	Frontiers in Immunology	Apremilast suppressed Th1/Th17 differentiation and enhanced Treg cells in CIA mouse model; histology confirmed reduced bone erosion — strongest preclinical mechanistic support
20525198	2010	In vitro / Mechanistic	Arthritis Research & Therapy	Apremilast inhibited spontaneous TNF-α production from human RA synovial tissue and reduced arthritis severity in two murine models — foundational mechanistic evidence
26097790	2014	PK Study	Clinical Pharmacology in Drug Development	No clinically meaningful pharmacokinetic interaction between Apremilast and methotrexate in PsA/RA patients — supports the safety of combination use
24797159	2014	Drug Review	Drugs	Comprehensive first-approval review covering Apremilast's full clinical programme; documents the RA development history alongside PsA and psoriasis programmes
40283434	2025	Review	Journal of Clinical Medicine	Comparative review of rituximab, Apremilast, and upadacitinib as DMARDs; contextualises Apremilast's current positioning and mechanistic differentiation within the RA treatment landscape
33403021	2020	Systematic Review	Therapeutic Advances in Musculoskeletal Disease	Systematic analysis of shared targeted therapies across autoimmune diseases; directly supports the immunological overlap justifying Apremilast repurposing from PsA to RA
38499181	2024	Clinical Guideline	J American Academy of Dermatology	Perioperative management guidelines for systemic immunomodulatory agents including Apremilast; relevant safety framework for patients with inflammatory arthritis
32453211	2021	Case Report	Journal of Clinical Rheumatology	Successful use of Apremilast for rituximab-associated palmoplantar pustulosis in a seropositive RA patient — indirect evidence of immunomodulatory activity at the RA–skin disease interface
39895048	2025	Scoping Review	Arthritis Care & Research	Scoping review of tsDMARD pregnancy outcomes including Apremilast; relevant safety consideration for RA patients of childbearing age

Singapore Market Information

Apremilast (Otezla®) has no registered products with the Health Sciences Authority (HSA) in Singapore. Patients who require this drug must access it through special import, institutional compassionate use, or clinical trial pathways.

For reference, Apremilast holds regulatory approvals in the United States (FDA), European Union (EMA), Japan, and other jurisdictions for psoriatic arthritis, moderate-to-severe plaque psoriasis, and oral ulcers associated with Behçet's disease.

Safety Considerations

Please refer to the package insert for safety information, as formal warning and contraindication data were not captured in this Evidence Pack.

Based on the known clinical programme in psoriatic arthritis and psoriasis, the following safety signals are commonly cited in global prescribing information and may be relevant when considering RA use:

Gastrointestinal effects: Nausea, diarrhoea, and vomiting are the most frequently reported adverse events, particularly in the first two weeks of treatment
Weight loss: Clinically meaningful weight decrease has been observed; body weight should be monitored
Neuropsychiatric risk: Depression, depressed mood, and suicidal ideation/behaviour have been reported; careful benefit–risk assessment is warranted in patients with a history of psychiatric illness
Drug interactions: No significant PK interaction with methotrexate (PMID 26097790); however, strong CYP3A4 inducers (e.g., rifampicin) may substantially reduce Apremilast plasma levels

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for Apremilast in RA is scientifically sound — PDE4 inhibition targets the same Th1/Th17-driven inflammation that drives RA pathology — and early Phase 2 data provide biological proof of concept. However, the premature termination of the largest Phase 2 RCT (NCT01285310, n=237) and the complete absence of any Phase 3 programme represent major barriers. The current RA treatment landscape — featuring well-validated biologics (TNF inhibitors, IL-6R inhibitors, CD20 agents) and JAK inhibitors — sets a high efficacy bar that Apremilast has not demonstrated the ability to meet. Additionally, the drug is not registered in Singapore, adding regulatory and access complexity.

To proceed, the following is needed:

Obtain the official termination rationale for NCT01285310 (efficacy insufficiency vs safety signal vs commercial prioritisation decision)
Retrieve complete MOA and safety data from DrugBank and current global prescribing information (Otezla® US/EU package insert)
Define the intended patient niche: e.g., patients ineligible for biologics, those seeking an all-oral regimen, or combination strategies with conventional DMARDs
Conduct a Singapore HSA special import or compassionate use feasibility assessment
If proceeding to an investigator-initiated study, design a focused Phase 2 basket trial targeting the specific RA subpopulation most likely to benefit from PDE4 inhibition (e.g., biologic-naïve, low-to-moderate disease activity)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.